This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
The panels and featured speakers include a discussion on “Exploring the Value and Application of Botanical and Synthetic Formulations in Psychedelic Medicine,” in which Dr. Matt Johnson, Joel Stanley and David Drapkin will discuss clinical research on psychedelic compounds.
To view the full press release, visit https://ibn.fm/08xWd
About SRAX Inc.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.
Image sourced from Unsplash
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
